Shares of Grifols (GRFS) rose nearly 7% on Aug 21 following a report issued by Bloomberg, which stated that Canada-based Brookfield Asset Management is in talks with banks to raise funds worth €9.5 billion ($10.6 billion) in debt for its potential acquisition.Through these funds, Brookfield intends to refinance Grifols’ existing debt, which includes loans and high-yield bonds. While most of the funding will be in dollars, the participating banks would be requested to commit to providing the funds ‘before se ...

文章核心观点 - 公司开发了首个用于治疗和功能性治愈慢性乙型肝炎病毒(HBV)感染的重组多克隆治疗药物GIGA-2339 [1][4][5] - GIGA-2339包含超过1,000种完全人源化的重组抗HBV抗体,可复制人体自然免疫反应 [2][7] - GIGA-2339是公司重组多克隆抗体药物平台的一部分,是Grifols公司创新战略和致力于为患者和医疗专业人员提供下一代抗体药物的一部分 [3][5] 行业概况 - 目前现有疗法和疫苗仍无法治愈HBV,全球仍有2.96亿人感染HBV,每年导致超过80万人死亡 [6] - 现有药物只能抑制病毒复制,但无法显著降低病毒蛋白水平,无法彻底治愈 [6][7] 公司情况 - 公司利用行业领先的单细胞技术,开发用于治疗免疫缺陷、传染病和难治性肿瘤的创新性抗体药物 [16] - 公司的重组多克隆抗体技术平台可以捕获和重现完整的免疫细胞谱系,从而创造出首创的重组多克隆抗体治疗药物 [9] - 公司的主要股东是Grifols公司,Grifols是一家全球性的医疗保健公司,致力于改善全球人民的健康和福祉 [10][14] - Grifols专注于治疗免疫学、肝病、重症监护、肺病、血液病、神经病和传染病等多个治疗领域 [11] - Grifols拥有全球最大的血浆捐赠中心网络,在北美、欧洲、非洲、中东和中国设有超过390个捐赠中心 [12] - Grifols还提供输血医学解决方案、生命科学研究用生物原料以及医院、药房和医疗专业人员所需的工具、信息和服务 [13]

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for XEMBIFY provides added flexibility and convenience for patients with primary humoral immunodeficiencies Increasing adopt ...

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for XEMBIFY provides added flexibility and convenience for patients with primary humoral immunodeficiencies Increasing adopt ...

Key TakeawaysBrookfield and family member shareholders of Grifols are in talks to take the Spanish pharmaceutical firm private.The potential buyers asked the board for information so they could do due diligence.Both sides say no agreement has been reached. American depositary receipts (ADRs) of Grifols (GRFS) gained for a second day Tuesday on word Canadian investment manager Brookfield and family member shareholders are in talks to take the Spanish pharmaceutical company private.  Brookfield confirmed Mond ...

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other proteins in the p ...

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols’ strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other proteins in the p ...

文章核心观点 - 通过股权交易,Grifols将其在上海莱士(SRAAS)的20%股权出售给海尔集团,交易金额约为人民币125亿元(约16亿欧元) [1][3] - Grifols和SRAAS将延长双方的白蛋白独家分销协议10年,SRAAS还有选择权将其延长至2044年 [4] - 此次交易将有助于Grifols和海尔集团发挥协同效应,共同推动中国医疗健康体系的发展 [1][2][7] - Grifols将利用此次交易所得偿还债务,以实现其去杠杆的承诺 [6] 根据目录分别总结 交易概况 - Grifols出售其在SRAAS 20%的股权给海尔集团 [1][3] - 交易金额为人民币125亿元(约16亿欧元) [3] - Grifols仍保留SRAAS 6.58%的经济权益,并在董事会中保留一个席位 [3] 战略合作 - Grifols和海尔集团将通过此次交易建立战略联盟,发挥各自在血浆和诊断、医疗健康解决方案等领域的优势,推动SRAAS的长期发展 [2][7] - 双方将延长白蛋白独家分销协议10年,SRAAS还有选择权将其延长至2044年,以满足中国不断增长的白蛋白需求 [4][5] 交易目的 - 此次交易有助于Grifols维持在中国的业务布局和与SRAAS的商业合作,同时也将帮助Grifols实现其去杠杆的承诺 [6]

With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest's portfolio and is manufactured with an innovative process at Biotest's new FDA-certified ‘Next Level' facility U.S. approval of Yimmugo paves the way for other Biotest proteins in late-stage development, including fibrinogen and trimodulin Launching Yimmu ...

With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest’s portfolio and is manufactured with an innovative process at Biotest’s new FDA-certified ‘Next Level’ facility U.S. approval of Yimmugo paves the way for other Biotest proteins in late-stage development, including fibrinogen and trimodulin Launching Yimmu ...